Psyllium: Difference between revisions
Kiran Singh (talk | contribs) No edit summary |
m (Protected "Psyllium": Bot: Protecting all pages from category Drug ([Edit=Allow only administrators] (indefinite) [Move=Allow only administrators] (indefinite))) |
||
| (One intermediate revision by one other user not shown) | |||
| Line 2: | Line 2: | ||
|authorTag={{KS}} | |authorTag={{KS}} | ||
|OTC=Yes | |OTC=Yes | ||
|genericName=psyllium husk | |genericName=psyllium husk | ||
|aOrAn=a | |aOrAn=a | ||
|drugClass=laxative | |drugClass=laxative | ||
|indicationType=treatment | |indicationType=treatment | ||
|indication=[[constipation]] | |indication=[[constipation]] | ||
|adverseReactions=borborygmi and flatulence | |adverseReactions=borborygmi and flatulence | ||
|blackBoxWarningTitle=<span style="color:#FF0000;">ConditionName: </span> | |blackBoxWarningTitle=<span style="color:#FF0000;">ConditionName: </span> | ||
| Line 25: | Line 24: | ||
* 5 capsules one to three times daily | * 5 capsules one to three times daily | ||
|offLabelAdultGuideSupport=* There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in adult patients. | |offLabelAdultGuideSupport=* There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in adult patients. | ||
|offLabelAdultNoGuideSupport===Indications== | |offLabelAdultNoGuideSupport===Indications== | ||
* Constipation | * Constipation | ||
* Gastrointestinal symptom, Orlistat-induced | * Gastrointestinal symptom, Orlistat-induced | ||
* Hypercholesterolemia | * Hypercholesterolemia | ||
|fdaLIADPed===Indications== | |fdaLIADPed===Indications== | ||
| Line 46: | Line 40: | ||
* Consult a doctor | * Consult a doctor | ||
|offLabelPedGuideSupport=* There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients. | |offLabelPedGuideSupport=* There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients. | ||
|offLabelPedNoGuideSupport=* There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients. | |offLabelPedNoGuideSupport=* There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients. | ||
|warnings=* '''Choking''' Taking this product without adequate fluid may cause it to swell and block your throat or esophagus and may cause choking. Do not take this product if you have difficulty in swallowing. If you experience chest pain, vomiting or difficulty in swallowing or breathing after taking this product, seek immediate medical attention. | |warnings=* '''Choking''' Taking this product without adequate fluid may cause it to swell and block your throat or esophagus and may cause choking. Do not take this product if you have difficulty in swallowing. If you experience chest pain, vomiting or difficulty in swallowing or breathing after taking this product, seek immediate medical attention. | ||
| Line 66: | Line 56: | ||
* You experience rectal bleeding or fail to have a bowel movement, as these may be signs of a serious condition | * You experience rectal bleeding or fail to have a bowel movement, as these may be signs of a serious condition | ||
|clinicalTrials=* There is limited information regarding <i>Clinical Trial Experience</i> of {{PAGENAME}} in the drug label. | |clinicalTrials=* There is limited information regarding <i>Clinical Trial Experience</i> of {{PAGENAME}} in the drug label. | ||
|postmarketing=* There is limited information regarding <i>Postmarketing Experience</i> of {{PAGENAME}} in the drug label. | |postmarketing=* There is limited information regarding <i>Postmarketing Experience</i> of {{PAGENAME}} in the drug label. | ||
|useInPregnancyAUS=* There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of {{PAGENAME}} in women who are pregnant. | |useInPregnancyAUS=* There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of {{PAGENAME}} in women who are pregnant. | ||
|useInLaborDelivery=There is no FDA guidance on use of {{PAGENAME}} during labor and delivery. | |useInLaborDelivery=There is no FDA guidance on use of {{PAGENAME}} during labor and delivery. | ||
| Line 85: | Line 69: | ||
|useInReproPotential=There is no FDA guidance on the use of {{PAGENAME}} in women of reproductive potentials and males. | |useInReproPotential=There is no FDA guidance on the use of {{PAGENAME}} in women of reproductive potentials and males. | ||
|useInImmunocomp=There is no FDA guidance one the use of {{PAGENAME}} in patients who are immunocompromised. | |useInImmunocomp=There is no FDA guidance one the use of {{PAGENAME}} in patients who are immunocompromised. | ||
|administration=* Oral | |administration=* Oral | ||
* Take this product (child or adult dose) with at least 8 ounces (a full glass0 of water or other fluid. Taking this product without enough liquid may cause choking. See choking warning. | * Take this product (child or adult dose) with at least 8 ounces (a full glass0 of water or other fluid. Taking this product without enough liquid may cause choking. See choking warning. | ||
|monitoring=* There is limited information regarding <i>Monitoring</i> of {{PAGENAME}} in the drug label. | |monitoring=* There is limited information regarding <i>Monitoring</i> of {{PAGENAME}} in the drug label. | ||
| Line 98: | Line 78: | ||
<!--IV Compatibility--> | <!--IV Compatibility--> | ||
|IVCompat=There is limited information regarding <i>IV Compatibility</i> of {{PAGENAME}} in the drug label. | |IVCompat=There is limited information regarding <i>IV Compatibility</i> of {{PAGENAME}} in the drug label. | ||
|overdose=* There is limited information regarding <i>Chronic Overdose</i> of {{PAGENAME}} in the drug label. | |overdose=* There is limited information regarding <i>Chronic Overdose</i> of {{PAGENAME}} in the drug label. | ||
| Line 105: | Line 83: | ||
<!--Drug box 2--> | <!--Drug box 2--> | ||
|mechAction=* | |mechAction=* | ||
|structure=* | |||
|structure=* | |||
|PD=There is limited information regarding <i>Pharmacodynamics</i> of {{PAGENAME}} in the drug label. | |PD=There is limited information regarding <i>Pharmacodynamics</i> of {{PAGENAME}} in the drug label. | ||
|PK=There is limited information regarding <i>Pharmacokinetics</i> of {{PAGENAME}} in the drug label. | |PK=There is limited information regarding <i>Pharmacokinetics</i> of {{PAGENAME}} in the drug label. | ||
|nonClinToxic=There is limited information regarding <i>Nonclinical Toxicology</i> of {{PAGENAME}} in the drug label. | |nonClinToxic=There is limited information regarding <i>Nonclinical Toxicology</i> of {{PAGENAME}} in the drug label. | ||
|clinicalStudies=There is limited information regarding <i>Clinical Studies</i> of {{PAGENAME}} in the drug label. | |clinicalStudies=There is limited information regarding <i>Clinical Studies</i> of {{PAGENAME}} in the drug label. | ||
|howSupplied=* | |howSupplied=* | ||
|fdaPatientInfo=There is limited information regarding <i>Patient Counseling Information</i> of {{PAGENAME}} in the drug label. | |fdaPatientInfo=There is limited information regarding <i>Patient Counseling Information</i> of {{PAGENAME}} in the drug label. | ||
|alcohol=* Alcohol-{{PAGENAME}} interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication. | |alcohol=* Alcohol-{{PAGENAME}} interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication. | ||
|brandNames=* KONSYL 100 PERCENT NATURAL PSYLLIUM FIBER ®<ref>{{Cite web | title =psyllium husk capsule| url =http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ab185f98-fe41-41e5-991d-0ea37dfa5958 }}</ref> | |brandNames=* KONSYL 100 PERCENT NATURAL PSYLLIUM FIBER ®<ref>{{Cite web | title =psyllium husk capsule| url =http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ab185f98-fe41-41e5-991d-0ea37dfa5958 }}</ref> | ||
|lookAlike=* A® — B®<ref name="www.ismp.org">{{Cite web | last = | first = | title = http://www.ismp.org | url = http://www.ismp.org | publisher = | date = }}</ref> | |lookAlike=* A® — B®<ref name="www.ismp.org">{{Cite web | last = | first = | title = http://www.ismp.org | url = http://www.ismp.org | publisher = | date = }}</ref> | ||
|drugShortage= | |drugShortage= | ||
}} | }} | ||
Latest revision as of 17:01, 20 August 2015
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Kiran Singh, M.D. [2]
Disclaimer
WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.
NOTE: Most over the counter (OTC) are not reviewed and approved by the FDA. However, they may be marketed if they comply with applicable regulations and policies. FDA has not evaluated whether this product complies.
Overview
Psyllium is a laxative that is FDA approved for the treatment of constipation. Common adverse reactions include borborygmi and flatulence.
Adult Indications and Dosage
FDA-Labeled Indications and Dosage (Adult)
Indications
- For relief of occasional constipation and to induce regularity. This product generally produces bowel movement within 12 to 72 hours
Dosage
- 5 capsules one to three times daily
Off-Label Use and Dosage (Adult)
Guideline-Supported Use
- There is limited information regarding Off-Label Guideline-Supported Use of Psyllium in adult patients.
Non–Guideline-Supported Use
Indications
- Constipation
- Gastrointestinal symptom, Orlistat-induced
- Hypercholesterolemia
Pediatric Indications and Dosage
FDA-Labeled Indications and Dosage (Pediatric)
Indications
- For relief of occasional constipation and to induce regularity. This product generally produces bowel movement within 12 to 72 hours
Dosage
Children 12 years and over
- 5 capsules one to three times daily
Children under 12 years
- Consult a doctor
Off-Label Use and Dosage (Pediatric)
Guideline-Supported Use
- There is limited information regarding Off-Label Guideline-Supported Use of Psyllium in pediatric patients.
Non–Guideline-Supported Use
- There is limited information regarding Off-Label Non–Guideline-Supported Use of Psyllium in pediatric patients.
Contraindications
There is limited information regarding Psyllium Contraindications in the drug label.
Warnings
- Choking Taking this product without adequate fluid may cause it to swell and block your throat or esophagus and may cause choking. Do not take this product if you have difficulty in swallowing. If you experience chest pain, vomiting or difficulty in swallowing or breathing after taking this product, seek immediate medical attention.
DO NOT USE
- When abdominal pain, nausea or vomiting are present unless directed by a doctor
- If constipation lasts more than seven days
- If you have difficulty swallowing
ASK A DOCTOR BEFORE USE IF YOU HAVE
- Noticed a sudden change in bowel habits that persists over a period of 2 weeks.
Stop use and ask a doctor if
- You experience rectal bleeding or fail to have a bowel movement, as these may be signs of a serious condition
Adverse Reactions
Clinical Trials Experience
- There is limited information regarding Clinical Trial Experience of Psyllium in the drug label.
Postmarketing Experience
- There is limited information regarding Postmarketing Experience of Psyllium in the drug label.
Drug Interactions
There is limited information regarding Psyllium Drug Interactions in the drug label.
Use in Specific Populations
Pregnancy
Pregnancy Category (FDA):
There is no FDA guidance on usage of Psyllium in women who are pregnant.
Pregnancy Category (AUS):
- There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Psyllium in women who are pregnant.
Labor and Delivery
There is no FDA guidance on use of Psyllium during labor and delivery.
Nursing Mothers
There is no FDA guidance on the use of Psyllium with respect to nursing mothers.
Pediatric Use
There is no FDA guidance on the use of Psyllium with respect to pediatric patients.
Geriatic Use
There is no FDA guidance on the use of Psyllium with respect to geriatric patients.
Gender
There is no FDA guidance on the use of Psyllium with respect to specific gender populations.
Race
There is no FDA guidance on the use of Psyllium with respect to specific racial populations.
Renal Impairment
There is no FDA guidance on the use of Psyllium in patients with renal impairment.
Hepatic Impairment
There is no FDA guidance on the use of Psyllium in patients with hepatic impairment.
Females of Reproductive Potential and Males
There is no FDA guidance on the use of Psyllium in women of reproductive potentials and males.
Immunocompromised Patients
There is no FDA guidance one the use of Psyllium in patients who are immunocompromised.
Administration and Monitoring
Administration
- Oral
- Take this product (child or adult dose) with at least 8 ounces (a full glass0 of water or other fluid. Taking this product without enough liquid may cause choking. See choking warning.
Monitoring
- There is limited information regarding Monitoring of Psyllium in the drug label.
IV Compatibility
There is limited information regarding IV Compatibility of Psyllium in the drug label.
Overdosage
- There is limited information regarding Chronic Overdose of Psyllium in the drug label.
Pharmacology
There is limited information regarding Psyllium Pharmacology in the drug label.
Mechanism of Action
Structure
Pharmacodynamics
There is limited information regarding Pharmacodynamics of Psyllium in the drug label.
Pharmacokinetics
There is limited information regarding Pharmacokinetics of Psyllium in the drug label.
Nonclinical Toxicology
There is limited information regarding Nonclinical Toxicology of Psyllium in the drug label.
Clinical Studies
There is limited information regarding Clinical Studies of Psyllium in the drug label.
How Supplied
Storage
There is limited information regarding Psyllium Storage in the drug label.
Images
Drug Images
{{#ask: Page Name::Psyllium |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}
Package and Label Display Panel
{{#ask: Label Page::Psyllium |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}
Patient Counseling Information
There is limited information regarding Patient Counseling Information of Psyllium in the drug label.
Precautions with Alcohol
- Alcohol-Psyllium interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.
Brand Names
- KONSYL 100 PERCENT NATURAL PSYLLIUM FIBER ®[1]
Look-Alike Drug Names
- A® — B®[2]
Drug Shortage Status
Price
References
The contents of this FDA label are provided by the National Library of Medicine.
- ↑ "psyllium husk capsule".
- ↑ "http://www.ismp.org". External link in
|title=(help)
{{#subobject:
|Page Name=Psyllium
|Pill Name=No image.jpg
|Drug Name=
|Pill Ingred=|+sep=;
|Pill Imprint=
|Pill Dosage={{{dosageValue}}} {{{dosageUnit}}}
|Pill Color=|+sep=;
|Pill Shape=
|Pill Size (mm)=
|Pill Scoring=
|Pill Image=
|Drug Author=
|NDC=
}}
{{#subobject:
|Label Page=Psyllium |Label Name=Psyllium11.png
}}
{{#subobject:
|Label Page=Psyllium |Label Name=Psyllium11.png
}}